ID   HO-1-u-1
AC   CVCL_2784
SY   HO-1-U-1; Ho-1-u-1; HO1-U-1; HO1-U1; Ho-1U1; HO1U1; HO1u1; Ho1u1; Ueda-1
DR   BTO; BTO:0005948
DR   CLO; CLO_0051384
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 864
DR   BioSample; SAMN01821683
DR   BioSample; SAMN03472521
DR   cancercelllines; CVCL_2784
DR   Cell_Model_Passport; SIDM00591
DR   Cosmic; 753561
DR   Cosmic; 1118792
DR   Cosmic; 1120707
DR   Cosmic; 1530742
DR   Cosmic; 1571800
DR   Cosmic; 1995441
DR   Cosmic; 2266788
DR   Cosmic; 2546834
DR   Cosmic-CLP; 753561
DR   DepMap; ACH-002045
DR   EGA; EGAS00001000978
DR   GDSC; 753561
DR   GEO; GSM827216
DR   GEO; GSM850381
DR   GEO; GSM1669889
DR   JCRB; JCRB0828
DR   LINCS_LDP; LCL-1202
DR   PharmacoDB; HO1u1_560_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_2784
DR   RCB; RCB2102
DR   TKG; TKG 0455
DR   Wikidata; Q54890083
RX   DOI=10.5794/jjoms.31.1347;
RX   PubMed=9290701;
RX   PubMed=12738951;
RX   PubMed=17079100;
RX   PubMed=17325662;
RX   PubMed=19071203;
RX   PubMed=20215515;
RX   PubMed=25448555;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=32990596;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Characteristics: Suitable for in vitro sublingual drug delivery screening involving passive diffusion (PubMed=17079100; PubMed=19071203).
CC   Doubling time: ~23 hours (DOI=10.5794/jjoms.31.1347).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=1.54%; Native American=0%; East Asian, North=76.45%; East Asian, South=19.98%; South Asian=0.41%; European, North=1.61%; European, South=0% (PubMed=30894373).
CC   Misspelling: HO1-UI; Cosmic=2546834.
CC   Derived from site: In situ; Salivary gland, sublingual gland; UBERON=UBERON_0001832.
ST   Source(s): Cosmic-CLP; JCRB; RCB; TKG
ST   Amelogenin: X,Y
ST   CSF1PO: 10
ST   D13S317: 9
ST   D16S539: 12
ST   D5S818: 10
ST   D7S820: 9,10
ST   TH01: 9
ST   TPOX: 10
ST   vWA: 17,19
DI   NCIt; C4041; Floor of mouth squamous cell carcinoma
DI   ORDO; Orphanet_502363; Squamous cell carcinoma of the oral cavity
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   72Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 36
//
RX   DOI=10.5794/jjoms.31.1347;
RA   Miyauchi S., Moroyama T., Sakamoto T., Okamoto T., Takada K.;
RT   "Establishment of human tumor cell line (Ueda-1) derived from squamous
RT   cell carcinoma of the floor of the mouth.";
RL   Nihon Koku Geka Gakkai Zasshi 31:1347-1351(1985).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=12738951; DOI=10.1067/moe.2003.36;
RA   Sugiyama M., Bhawal U.K., Dohmen T., Ono S., Miyauchi M., Ishikawa T.;
RT   "Detection of human papillomavirus-16 and HPV-18 DNA in normal,
RT   dysplastic, and malignant oral epithelium.";
RL   Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 95:594-600(2003).
//
RX   PubMed=17079100; DOI=10.1016/j.ijpharm.2006.10.012;
RA   Wang Y.-F., Zuo Z., Lee K.K.-H., Chow M.S.-S.;
RT   "Evaluation of HO-1-u-1 cell line as an in vitro model for sublingual
RT   drug delivery involving passive diffusion -- initial validation
RT   studies.";
RL   Int. J. Pharm. 334:27-34(2007).
//
RX   PubMed=17325662; DOI=10.1038/sj.onc.1210330;
RA   Nakaya K., Yamagata H.D., Arita N., Nakashiro K.-i., Nose M., Miki T.,
RA   Hamakawa H.;
RT   "Identification of homozygous deletions of tumor suppressor gene FAT
RT   in oral cancer using CGH-array.";
RL   Oncogene 26:5300-5308(2007).
//
RX   PubMed=19071203; DOI=10.1016/j.ijpharm.2008.11.010;
RA   Wang Y.-F., Zuo Z., Chow M.S.-S.;
RT   "HO-1-u-1 model for screening sublingual drug delivery -- influence of
RT   pH, osmolarity and permeation enhancer.";
RL   Int. J. Pharm. 370:68-74(2009).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=25448555; DOI=10.1016/j.ijpharm.2014.11.040;
RA   Vacher G., Sublet E., Gurny R., Borchard G.;
RT   "Establishment and first characterization of a sublingual epithelial
RT   and immune cell co-culture model.";
RL   Int. J. Pharm. 482:61-67(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=32990596; DOI=10.7554/eLife.57761;
RA   Chai A.W.Y., Yee P.S., Price S., Yee S.M., Lee H.M., Tiong V.K.H.,
RA   Goncalves E., Behan F.M., Bateson J., Gilbert J.G.R., Tan A.-C.,
RA   McDermott U., Garnett M.J., Cheong S.-C.;
RT   "Genome-wide CRISPR screens of oral squamous cell carcinoma reveal
RT   fitness genes in the Hippo pathway.";
RL   eLife 9:e57761.1-e57761.34(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//